Form 4 for ANIX Anixa Biosciences Inc
Accepted 2025-12-16 00:00:00 ET · period of report 2025-12-15 · accession 0001493152-25-027904 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-16 | 2025-12-15 | ANIX | Titterton Lewis H jr | Dir | M - OptEx | $2.92 | +16.0K | 969.3K | +2% | +$46.7K |
| D | 2025-12-16 | 2025-12-15 | ANIX | Titterton Lewis H jr | Dir | M - OptEx | $0.00 | -16.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-15 | M | A | 16,000 | $2.92 | 969,334 | D | — | — | |
| 2 | Derivative | Employee Stock Option | 2025-12-15 | M | D | 16,000 | $0.00 | 0 | D | $2.92 · 2016-02-18 to 2026-02-18 | 16,000 Common Stock | (F1) Right-To-Buy, pursuant to a stock option grant dated February 18, 2016. |